Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nammi Therapeutics Inc
Pfizer
IDEAYA Biosciences
Zumutor Biologics Inc.
National Cancer Institute (NCI)
SystImmune Inc.
Mayo Clinic
Merck Sharp & Dohme LLC
Exelixis
Myeloid Therapeutics
Genentech, Inc.
Innate Pharma
Dren Bio
LG Chem
Incyte Corporation
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Jonsson Comprehensive Cancer Center
MacroGenics
Xencor, Inc.
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Bristol-Myers Squibb
Shattuck Labs, Inc.
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Molecular Templates, Inc.
Inhibrx Biosciences, Inc
RemeGen Co., Ltd.
Eli Lilly and Company
Pfizer
Xencor, Inc.
University of California, San Francisco
Aurigene Discovery Technologies Limited
Atreca, Inc.
University of Florida
Fate Therapeutics
Genome & Company
Cantargia AB
AvenCell Therapeutics, Inc.
Tempest Therapeutics
Fate Therapeutics